Tomasz Skirecki

TL;DR: The authors reviewed the intricacies of COVID-19 pathophysiology, its various phenotypes, and the anti-SARS-CoV-2 host response at the humoral and cellular levels.

TL;DR: The role of key immune cells, the cause of lymphopenia, organ-specific immunology, the dynamics of sepsis-associated immunological alterations, the role of the microbiome, the standardisation of immunological tests, the development of better animal models, and the opportunities offered by immunotherapy are discussed.

TL;DR: The reasons for this failure are analyzed, focusing on the inclusion of inappropriate patients and the use of irrelevant animal models, and some putative approaches are listed that could help save lives and improve survivorship.

TL;DR: Scaffolds based on polycaprolactone (PCL), which is widely considered a suitable MSC delivery system, were used as a three‐dimensional culture environment promoting osteogenic differentiation of ADSCs and it is postulate that the 3D architecture is a critical factor and provides a useful environment for prior‐to‐implantation osteogenic differentiate of ADSC.

TL;DR: Focus is given on SARS-CoV-2 immunopathogenesis in the context of experimental therapies and preclinical evidence and their applicability in supporting efficacious clinical trial planning and the potential application of translational technology for epidemiological predictions, patient monitoring, and treatment decision-making in COVID-19.